Rule of thumb:

Tim, pls find time to read Great ideas!

Thursday, April 01, 2010

FT in week 14

1:26 PM

3 Group could wake Hutchison from Groundhog Day
By Paul Betts and Tom Mitchell / Published: March 31 2010 03:00

No only me in Groundhog day! Hutchison also.

Behind all successes are a series of failures
By Luke Johnson / Published: March 30 2010 21:58

Keep busy – never retreat from the fray entirely. Take exercise, research other possibilities, network furiously, redouble your efforts and seek advice about alternatives. As Winston Churchill said: “Never give in, never give in, never; never; never.”

Set new goals as soon as possible, keep occupied by planning fresh adventures, and retain your thirst for experimentation. As Gordon Moore, co-founder of Intel, put it: “Failures are not something to be avoided. You want to have them happen as quickly as possible so you can make progress rapidly.”

We live in a far from perfect world, and this is the phase in the cycle when things are apt to go awry. But educating yourself to cope with each misfortune, while soldiering on relentlessly, is the surest formula for glory I know.

Teller of hard truths to technologists
By Jonathan Guthrie / Published: March 30 2010 21:58

Backer to the future

Hermann Hauser has backed a succession of innovative UK businesses including:

Arm Holdings
Mr Hauser started the chip design business as a unit of Acorn Computers in 1981 with “no people and no money”. He helped spin it out from Acorn, by then part of Olivetti, in 1990. Arm is listed on the London Stock Exchange and has a market capitalisation of more than £3bn, thanks to the widespread use of its chips in mobile phones and other devices.

Originally known as Cambridge Silicon Radio, this business came to prominence as a designer of chips for Bluetooth wireless headsets. Amadeus, the venture capital firm co-founded by Mr Hauser, backed the spin-out from a consultancy in 1998. Shares in CSR, which floated in 2004, have been volatile, recovering some lost ground in the past 12 months to give the company a valuation of about £870m.

This genome analysis business received early-stage investment from Amadeus. Solexa’s aim was to cut the cost of genetic analysis to make it more accessible to patients and physicians. It was bought by Illumina, a California genetics business, in an all-share transaction that valued the UK company at about $600m in 2007.


Post a Comment